Trials / Completed
CompletedNCT06411860
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | Participants will receive a subcutaneous (SC) injection of placebo. |
| DRUG | Olpasiran | Participants will receive a SC injection of olpasiran at dose level 1 or 2. |
| DRUG | Moxifloxacin | Participants will receive a single dose of moxifloxacin as an oral tablet by mouth. |
Timeline
- Start date
- 2024-09-12
- Primary completion
- 2024-11-29
- Completion
- 2024-12-11
- First posted
- 2024-05-13
- Last updated
- 2025-10-27
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06411860. Inclusion in this directory is not an endorsement.